Compare FLYX & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLYX | NSPR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.2M | 81.8M |
| IPO Year | N/A | N/A |
| Metric | FLYX | NSPR |
|---|---|---|
| Price | $7.50 | $1.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 20.1K | ★ 56.0K |
| Earning Date | 02-22-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $362,955,000.00 | $7,779,000.00 |
| Revenue This Year | $28.47 | $22.76 |
| Revenue Next Year | $22.44 | $75.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.38 | 14.04 |
| 52 Week Low | $1.90 | $1.59 |
| 52 Week High | $6.90 | $3.80 |
| Indicator | FLYX | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 76.85 | 42.83 |
| Support Level | $3.08 | $1.78 |
| Resistance Level | $4.50 | $1.95 |
| Average True Range (ATR) | 0.59 | 0.15 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 71.75 | 29.41 |
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.